Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06063603
Other study ID # ASCENT
Secondary ID NCI-2023-05223AS
Status Recruiting
Phase N/A
First received
Last updated
Start date May 25, 2023
Est. completion date May 25, 2026

Study information

Verified date March 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial tests how well a pain management intervention preparatory to a future pragmatic trial works in rural dwelling and Hispanic cancer survivors. Cancer pain is a key case study in health disparities in the United States. Cancer pain is prevalent, under treated, and remains a major cause of suffering, impairment, and disability for millions of Americans. Individual pain interventions and care models show promise for cancer pain in controlled settings. Hispanic and rural-dwelling cancer survivors stand to benefit the most from electronic health record innovations, as each of these health disparities populations experience profound disparities in pain outcomes, including marked under- and over-prescribing of opioids. Additionally, Hispanics not only comprise a steadily growing proportion of cancer survivors, but are also increasingly immigrating to rural communities, potentially placing them at "double risk" for poor outcomes. This trial will allow for the refinement of pain management intervention components that could help the management of cancer-related pain in rural dwelling and Hispanic cancer survivors.


Description:

PRIMARY OBJECTIVE: I. To refine and pilot test components of a validated collaborative care model-based intervention aimed at improving pain control among rural dwelling and Hispanic cancer survivors. OUTLINE: Participants are assigned to 1 of 3 groups. GROUP I: Participants meet with pain care manager (PCM) and community health worker (CHW) via telephone or video visit to discuss the cancer-related pain. Participants receive self-guided pain management education materials and receive an action plan with suggestions or referrals to participate in tier 1 interventions that include exercise, cognitive behavioral therapy, medication and/or tier 2 interventions that include integrative medicine (massage, acupuncture and mindfulness relaxation), spiritual support, pain clinic referral and palliative and spiritual care referrals during the intake visit. Participants undergo a planning visit 2 weeks later to give an update on their pain and may receive additional resources from the PCM and/or CHW. Participants then undergo a final visit 4 weeks later with the PCM and/or CHW and receive final recommendations and referrals. Participants may receive a follow up call between intake and visit 2 and/or between visit 2 and the final visit from the CHW or PCM to assess pain levels on study. GROUP II: ASCENT study interventionists complete an interview on study. GROUP III: Medical oncology providers participate in a focus group on study.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date May 25, 2026
Est. primary completion date May 25, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - A qualifying liquid or solid cancer diagnosis with visits at a participating Mayo site - Age 18+ - Numerical rating scale (NRS) pain score of a 5+ out of 10 - Pain that developed (onset) or significantly worsened since cancer diagnosis - Malignant hematology including: - Lymphoma - Myeloma - Chronic leukemias Exclusion Criteria: - Patient Health Questionnaire (PHQ) 8 score of 10 or more - Life expectancy less than 12 months - Hospice enrollment - Admitted to hospital from long term care/skilled nursing facilities (SNF) - Acute leukemias - Primary brain tumors - Confinement to a bed or a chair more than a third of waking hours because of health complications

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Acupuncture Therapy
Undergo acupuncture therapy
Behavioral:
Cancer Pain Management
Receive pain clinic referral
Cognitive Behavior Therapy
Undergo CBT
Procedure:
Discussion
Participate in focus group
Other:
Educational Intervention
Receive self-guided pain management education materials
Exercise
Participate in exercise
Interview
Complete interview
Procedure:
Massage Therapy
Receive massage
Behavioral:
Mindfulness Relaxation
Practice mindfulness
Procedure:
Pain Therapy
Receive pain treatment/medicine
Other:
Palliative Therapy
Receive palliative care referral
Behavioral:
Patient Navigation
Undergo visits with PCM and CHW for pain management
Other:
Referral
Receive pain management referrals
Procedure:
Spiritual Therapy
Receive spiritual support
Spiritual Care Referral
Receive spiritual care referral
Other:
Survey Administration
Ancillary studies

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota
United States Mayo Clinic in Arizona Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Usability and acceptability of recruitment message Assessed by the proportion of patients calling the ASCENT 1-800 line to express interest Up to 3 years
Primary Usability and acceptability of the PCIG (Patient Global Impression of Change) Questionnaire recruitment component Assessed by the proportion of participants who open and completed the PCIG Questionnaire, a 0-6 scale where 0 is very much improved and 6 is very much worse Baseline; Up to 3 years
Primary Usability and acceptability of the EQ-5D-3L (European Quality of Life 5 Dimensions 3 Level Version) recruitment component Assessed by the proportion of participants who open and completed the EQ-5D-3L questionnaire. Page 1 of the EQ-5D-3L descriptive system is comprised of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. Responses are expressed in a 5-digit number that describes the patient's health state.Page 2 is a vertical visual analog (sliding) scale (VAS) with the opposite endpoints labeled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement. Baseline; Up to 3 years
Primary Usability and acceptability of the PCS (Pain Catastrophizing Scale) recruitment component Assessed by the proportion of participants who open and completed the PCS Questionnaire, which consists of 13 statements containing a number of thoughts and feelings one may experience when having pain. The items are divided into the categories of rumination, magnification and helplessness, with each item scored on a 5-point scale where 0=Not at all; 1=to a Slight Degree; 2=To a Moderate Degree; 3=To a Great Deal; and 4=All the Time. Baseline; Up to 3 years
Primary Usability and acceptability of the Patient Health Questionnaire (PHQ-8) recruitment component Assessed by the proportion of participants who open and completed the PHQ-8, a depression measure which consists of 8 questions, with each item scored on a 4-point scale: Not at all; Several days; More than half the days; Nearly every day. Baseline; Up to 3 years
Primary Usability and acceptability of the Generalized Anxiety Disorder-7 (GAD-7) Questionnaire recruitment component Assessed by the proportion of participants who open and completed the GAD-7, an anxiety measure which consists of 7 questions, with each item scored on a 4-point scale: Not at all; Several days; More than half the days; Nearly every day. Baseline; Up to 3 years
Primary Usability and acceptability of the Pain Self Efficacy Questionnaire (PSEQ) recruitment component Assessed by the proportion of participants who open and completed the PSEQ, a 10-item questionnaire developed to assess the confidence people with ongoing pain have in performing activities while in pain. Each item is scored on a 0-6 scale where 0=Not at all confident and 6=Completely. Baseline; Up to 3 years
Primary Usability and acceptability of the Social Determinants of Health (SDOH) intake component Assessed by the proportion of participants who provide complete Social Determinants of Health (SDOH) histories by answering a series of 6 questions related to homelessness, safety in the home, health, and mood. Baseline; Up to 3 years
Primary Usability and acceptability of the Pain NRS (Numerical Rating Scale) intake component Assessed by the proportion of participants who complete the Pain NRS, a 0-10 scale where 0 is no pain and 10 is the worst pain imaginable Baseline; Up to 3 years
Primary Usability and acceptability of the Information Technology (IT) Assessment intake component Assessed by the proportion of participants who complete the IT Assessment, which consists of 4 questions related to technology access and usage. Up to 3 years
Primary Usability and acceptability of the Tobacco, Alcohol, Prescription Medication, and Other Substance use (TAPS) intake component Assessed by the proportion of participants who complete the TAPS-1 Questionnaire, the tool's first-stage screening component, which consists of five questions related to usage of four substance categories (tobacco, alcohol, prescriptions, or other substances) in the past 12 months. Response option are 0-Daily or Almost Daily, 1-Weekly, 2-Monthly, 3-Less Than Monthly, or 4-Never. Up to 3 years
Primary Usability and acceptability of the ASCENT Conversation Guide intake component - intervention Assessed by the proportion of participants who select a Tier 1 pain management intervention or request review of Tier 2 pain management options Up to 3 years
Primary Usability and acceptability of the ASCENT Conversation Guide intake component - engagement Assessed on an 11-point numerical rating scales (NRS) by Pain Care Managers and/or Community Health Workers who are conducting intake interviews. Up to 3 years
Primary Usability and acceptability of planning visit recommendation component - revision Assessed by the proportion of participants who request revisions to the recommended plan Up to 3 years
Primary Usability and acceptability of intake visit component - SMART Goal recommendation Assessed by the proportion of participants who develop a SMART (Specific, Measurable, Achievable, Relevant, and Time-Bound) Goal Up to 3 years
Primary Usability and acceptability of planning visit component - SMART Goal completion Assessed by the proportion of participants who complete a SMART (Specific, Measurable, Achievable, Relevant, and Time-Bound) Goal Up to 3 years
Primary Usability and acceptability of planning visit recommendation component - cancer pain intervention Assessed by the category of pain intervention selected during the planning visit as the initial focus of a multi-modal pain care plan, either Tier 1 (Exercise, Cognitive Behavior Therapy [CBT], and Medicine) or Tier 2 (Integrative Medicine [Massage, Acupuncture, Mindfulness], Spiritual Support, Pain Clinic Referrals, and/or Palliative and Spiritual Care Referrals). Up to 3 years
Primary Usability and acceptability of final visit - cancer pain management component Recorded as the category/ies of barriers impeding receipt of recommended pain care, as assessed by a brief survey Up to 3 years
Primary Usability and acceptability of follow-up visit - survey completion Assessed by the proportion of participants completing surveys by administration mode (electronic health record portal, video visit, or phone interview, or printed questionnaire) Up to 3 years
Primary Usability and acceptability of follow-up visit - cancer pain management Assessed by the proportion of participants completing surveys by administration mode, cause of pain escalation (categorical), and participant-perceived barriers (categorical). Up to 3 years
Primary Usability and acceptability of follow-up visit - barriers to pain care Assessed by participant-reported categories of barriers impeding receipt of recommended pain care Up to 3 years
Primary Participant response rates Overall participant response rates will be assessed according to the number of patient-reported outcome measure (PROM) assessments, recruitment questionnaires, and remote pain assessments completed. Up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1